Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,198.7
-15.0 (-0.47%)

 

  • STI Straits Times Index
    3,198.7
    -15.0 (-0.47%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,535.0
    0.8 (0.05%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,609.2
    -46.7 (-0.17%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,030.2
    54.8 (1.84%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,479.2
    78.5 (0.34%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,942.5
    13.7 (0.23%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,239.6M
  • Value: 1,113.8M
  • Rise: 156
  • Fall: 146
  • Unch: 512

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
AusGroup^0.052-
IPS Securex0.072-
OEL0.029-
YZJ Shipbldg SGD1.040+0.020
ESR-REIT0.550+0.005
Tritech0.023-
SunMoonFood^0.048+0.003
Sino Grandness0.032+0.003
Sen Yue0.031+0.005
Singtel3.130-0.040

World Indices

World Indices
Name Last Change
Nasdaq 9,817.2 +84.4
HSI 27,609.2 -46.6
HSCEI 10,914.0 +5.4
Jakarta 5,942.5 +13.7
Nikkei 225 23,479.2 +78.5
SSE Comp 3,030.2 +54.8
Shanghai A 3,175.4 +57.4
Shanghai B 244.1 +4.7
KOSPI 2,195.5 -14.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

NAVIDEA BIOPHARMACEUTICALS INC NAVIDEA BIOPHARMACEUTICALS
Updated on 19 Feb 2020 (End of trading day)
Last (USD): 1.040 Change: -0.030 High: 1.100 Remarks: -
Change (%): -2.80 Low: 1.010
Open 1.080 Yesterday's Close 1.07
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 177,909 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.09961 Trailing EPS (USD) e -0.06997 NAV (USD) b -0.0047
PE a - Trailing PE f - Price / NAV b -221.2766
Dividend (USD) d - Cash In Hand (USD) g 0.0175 Issued & Paid-up Shares c 22,578,000
Dividend Yield (%) d - Price / Cash In Hand g 59.429 Treasury Shares h -
Beta - 75 Daysi 1.043 R-Squared - 75 Days(%)i 2.12 Market Cap (M) 168.695
Beta - 500 Daysi 2.106 R-Squared - 500 Days (%)i 0.06 Enterprise Value (M) 167.348
Piotroski F Score 1 Exchange Code NAVB Par Value ( $ ) n.a.
52 Weeks Volatility (%) 110.77 Free Float (%) 49.2
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 19 Feb 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference NAVIDEA BIOPHARMACEUTICALS INC NYSE American 168.695 - - -221.2766 -
Industry Pharmaceuticals: Major NYSE American 121.217 - - 12.8140 -
Local Peer BIOMX INC NYSE American 224.828 - - - -
Local Peer AGEX THERAPEUTICS INC NYSE American 53.085 - - 12.2396 -
Local Peer ANNOVIS BIO INC NYSE American 38.261 - - - -
Global Peer JOHNSON & JOHNSON NYSE 392,415.197 25.653 25.927 - 2.404
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 245,711.884 19.439 20.904 - 1.733
Global Peer MERCK & CO INC NYSE 208,770.360 33.564 21.210 - 2.471
Global Peer PFIZER INC NYSE 200,501.168 17.979 12.322 - 3.935
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 154,036.068 31.308 44.791 - 1.697
Global Peer ABBVIE INC NYSE 139,216.115 24.610 17.730 - 4.196
Global Peer ELI LILLY AND COMPANY NYSE 135,215.249 41.836 29.154 - 1.759
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NYSE 129,407.685 60.152 96.354 - 2.683
Global Peer SANOFI SPON ADR ECH REP 1/2 ORD EUR2 LEVEL II NASDAQ 127,164.960 24.957 40.573 1.9223 2.264
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 119,464.598 19.539 20.444 13.8087 1.773
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), WUXI APPTEC (HKEx), HANSOH PHARMA (HKEx), SINOPHARM (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), CHINARES PHARMA (HKEx), REPLIGEN CORP (NASDAQ), SH PHARMA (HKEx), INNOVENT BIO-B (HKEx), BAIYUNSHAN PH (HKEx), NEKTAR THERAPEUTICS (NASDAQ), HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS (NASDAQ), CMS (HKEx), ALLAKOS INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), TRAD CHI MED (HKEx), SSY GROUP (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), HENLIUS-B (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), JUNSHI BIO-B (HKEx), CANSINOBIO-B (HKEx), PRINCIPIA BIOPHARMA INC (NASDAQ), FORTY SEVEN INC (NASDAQ), CHINAGRANDPHARM (HKEx), RA PHARMACEUTICALS INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), ZYMEWORKS INC (NYSE), TRICIDA INC (NASDAQ), AKCEA THERAPEUTICS INC (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), TONGRENTANGCM (HKEx), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), SPRINGWORKS THERAPEUTICS INC (NASDAQ), CSTONE PHARMA-B (HKEx), Y-MABS THERAPEUTICS INC (NASDAQ), CKLIFE SCIENCES (HKEx), UNITED LAB (HKEx), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), ATHENEX INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), OPKO HEALTH INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), PETIQ INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), PROVENTION BIO INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), SHINEWAY PHARM (HKEx), APREA THERAPEUTICS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), AC IMMUNE SA (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), IGBB (Bursa), NEOLEUKIN THERAPEUTICS INC (NASDAQ), HUA MEDICINE-B (HKEx), MILESTONE PHARMACEUTICALS INC (NASDAQ), 89BIO INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), FUSEN PHARM (HKEx), BEYONDSPRING INC (NASDAQ), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), BSTEAD (Bursa), SIGA TECHNOLOGIES INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), UROVANT SCIENCES LTD (NASDAQ), DURECT CORP (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), LANNETT CO INC (NYSE), GRITSTONE ONCOLOGY INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), EVOLUS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), Kimia Farma (Persero) Tbk. (IDX), AMAG PHARMACEUTICS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), TOT BIOPHARM-B (HKEx), DAWNRAYS PHARMA (HKEx), VERU INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), ARTARA THERAPEUTICS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), AKORN INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), HARROW HEALTH INC (NASDAQ), MILLENDO THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), MUSTANG BIO INC (NASDAQ), CH BIOTECH SER (HKEx), GAMIDA CELL LTD (NASDAQ), OBSEVA SA (NASDAQ), LIQUIDIA TECHNOLOGIES INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), MENLO THERAPEUTICS INC (NASDAQ), ZHONGZHIPHARM (HKEx), PHARMA (Bursa), CORVUS PHARMACEUTICALS INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), CLEARSIDE BIOMEDICAL INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), ASSERTIO THERAPEUTICS INC (NASDAQ), NC HEALTHCARE (HKEx), GENPREX INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), CHARMACY PHAR (HKEx), PAK FAH YEOW (HKEx), TREVI THERAPEUTICS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), NEW RAY MEDIC (HKEx), IX Biopharma (SGX), IMMUNIC INC (NASDAQ), MEDIWOUND LTD (NASDAQ), KOTRA (Bursa), EYENOVIA INC (NASDAQ), BAUDAX BIO INC (NASDAQ), PALLA PHARMA LTD (ASX), NEP INTERLONG (HKEx), Merck Tbk. (IDX), CNS PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), ONCTERNAL THERAPEUTICS INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), WAI YUEN TONG (HKEx), Phapros Tbk. (IDX), ENTERA BIO LTD (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), Hyphens Pharma (SGX), MEDLAB CLINICAL LIMITED (ASX), HOTH THERAPEUTICS INC (NASDAQ), NOVA (Bursa), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), PURAPHARM (HKEx), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), EXTRAWELL PHAR (HKEx), MANNATECH INC (NASDAQ), INVION LTD (ASX), SANAI HEALTH GP (HKEx), MOLECULIN BIOTECH INC (NASDAQ), IP (SET), BIOHLDG (Bursa), JCT (SET), EDESA BIOTECH INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), PHARMAXIS (ASX), CITIUS PHARMACEUTICALS INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), RACE ONCOLOGY LTD (ASX), CHINA SXT PHARMACEUTICALS INC (NASDAQ), NOXOPHARM LTD (ASX), PASHUN INT'L (HKEx), SINOLIFE UTD (HKEx), PROPHASE LABS INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), ACRUX (ASX), TALI DIGITAL LIMITED (ASX), AILERON THERAPEUTICS INC (NASDAQ), SPRING BANK PHARMACEUTICALS INC (NASDAQ), EXOPHARM LTD (ASX), ADIAL PHARMACEUTICALS INC (NASDAQ), IMMURON LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), CRESO PHARMA LTD (ASX), BRICKELL BIOTECH INC (NASDAQ), KITOV PHARMA LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), SUNZEN (Bursa), APPLIED DNA SCIENCES INC (NASDAQ), NOVAN INC (NASDAQ), CELLMID LIMITED (ASX), FARMAFORCE LTD (ASX), Merck Sharp Dohme Pharma Tbk. (IDX), NOVUS THERAPEUTICS INC (NASDAQ), SUDA PHARMACEUTICALS LTD (ASX), FIJI KAVA LTD (ASX), Pharmesis Intl (SGX), TBG DIAGNOSTICS LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.060
+6.12 %
10 Days --0.020
-1.89 %
20 Days --0.380
-26.76 %
Medium Term Return 3 Months -+0.360
+52.94 %
6 Months -+0.530
+103.92 %
1 Year --2.360
-69.41 %
Long Term Return 2 Years --5.860
-84.93 %
3 Years --8.762
-89.39 %
5 Years --32.360
-96.89 %
Annualised Return Annualised --
-50.04 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.490 - 4.200 Change From 1 Year Low +0.550 % Change From 1 Year Low (%) +112.24
Change From 1 Year High -3.160 % Change From 1 Year High (%) -75.24
2 Years Range 0.490 - 8.484 Change From 2 Years Low +0.550 % Change From 2 Years Low (%) +112.24
Change From 2 Years High -7.444 % Change From 2 Years High (%) -87.74
5 Years Range 0.490 - 49.900 Change From 5 Years Low +0.550 % Change From 5 Years Low (%) +112.24
Change From 5 Years High -48.860 % Change From 5 Years High (%) -97.92
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Historical Price Data

Date Open High Low Close Volume VWAP
19 Feb 2020 1.080 1.100 1.010 1.040 177,909 -
18 Feb 2020 1.240 1.240 1.050 1.070 231,606 -
14 Feb 2020 1.170 1.300 1.079 1.180 768,874 -
13 Feb 2020 0.960 1.000 0.950 0.980 97,075 -
12 Feb 2020 1.000 1.010 0.950 0.980 70,066 -
11 Feb 2020 0.975 1.040 0.975 1.000 41,335 -
10 Feb 2020 1.050 1.050 0.985 1.010 53,222 -
07 Feb 2020 1.040 1.090 0.980 1.050 232,803 -
06 Feb 2020 1.180 1.180 1.040 1.060 219,842 -
05 Feb 2020 1.140 1.180 1.110 1.140 146,343 -
04 Feb 2020 1.170 1.200 1.105 1.150 133,128 -
03 Feb 2020 1.170 1.222 1.160 1.170 39,190 -
31 Jan 2020 1.260 1.260 1.157 1.200 157,437 -
30 Jan 2020 1.240 1.300 1.180 1.210 174,166 -
29 Jan 2020 1.340 1.340 1.250 1.250 78,324 -
28 Jan 2020 1.310 1.356 1.281 1.340 15,405 -
27 Jan 2020 1.380 1.380 1.250 1.300 103,578 -
24 Jan 2020 1.470 1.470 1.330 1.380 77,568 -
23 Jan 2020 1.300 1.440 1.280 1.420 129,011 -
22 Jan 2020 1.430 1.460 1.270 1.300 268,646 -
21 Jan 2020 1.450 1.470 1.400 1.400 72,493 -
17 Jan 2020 1.440 1.490 1.410 1.450 95,685 -
Summary
Current 2 Weeks
(05 Feb 2020 to 19 Feb 2020)
1.140 1.300 0.950 1.040 2,039,075 -
Previous 2 Weeks
(22 Jan 2020 to 04 Feb 2020)
1.430 1.460 0.950 1.150 1,176,453 -
4 Weeks from
(20 Dec 2019 to 21 Jan 2020)
1.020 1.300 0.950 1.400 3,220,178 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.